Emerging small molecule drugs

Sophie Colin, Giulia Chinetti-Gbaguidi, Jan A Kuivenhoven, Bart Staels

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)
82 Downloads (Pure)


Dyslipidaemia is a major risk factor for cardiovascular diseases. Pharmacological lowering of LDL-C levels using statins reduces cardiovascular risk. However, a substantial residual risk persists especially in patients with type 2 diabetes mellitus. Because of the inverse association observed in epidemiological studies of HDL-C with the risk for cardiovascular diseases, novel therapeutic strategies to raise HDL-C levels or improve HDL functionality are developed as complementary therapy for cardiovascular diseases. However, until now most therapies targeting HDL-C levels failed in clinical trials because of side effects or absence of clinical benefits. This chapter will highlight the emerging small molecules currently developed and tested in clinical trials to pharmacologically modulate HDL-C and functionality including new CETP inhibitors (anacetrapib, evacetrapib), novel PPAR agonists (K-877, CER-002, DSP-8658, INT131 and GFT505), LXR agonists (ATI-111, LXR-623, XL-652) and RVX-208.

Original languageEnglish
Pages (from-to)617-630
Number of pages14
JournalHandbook of Experimental Pharmacology
Publication statusPublished - 2015

Cite this